Чтение онлайн

При оценке маркеров костного ремоделирования необходимо снижение значений маркеров резорбции (Cross Laps и т. д.), прирост маркеров новообразования (костная фракция щелочной фосфатазы, остеокальцин и т. д.).

А.Е. Каратеев. Лечение бисфосфонатами и патология пищевода. Современная ревматология. 2010. № 3: 72–78.

О.М. Лесняк. Падения как важная составная часть проблемы переломов у пожилых людей // РМЖ 04 августа 2008 г. № 17.

С. 1142–1147.

Осложнения фармакотерапии. Неблагоприятные побочные реакции лекарственных средств. Том 1 / Под ред. Д.В. Рейхарта. М.: Литтерра, 2007. 256 с. (серия «Осложнения фармакотерапии»).

Abrahamsen B. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. Apr 23, 2009. 360(17): 1789.

Abrahamsen B., Eiken P., Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates // J. Internal Medicine. 2009. Vol. 265. Р. 581–592.

Advisory Task Force on Bisphosphonaterelated osteonecrosis of the Jaws // American Association of oral and maxillofacial surgeons. American Association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws // J. Oral Maxillofac Surg. 2007.Vol. 65. Р. 369–376.

Anderson P.H., O’Loughlin P.D., May B.K., Morris H.A. Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels. Bone 2005, 36, 654–662.

Baroutsou B., Babiolakis D., Stamatiadou A. et al. Patient compliance and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal women // Ann. Rheum. Dis. 2004. V. 63 (Suppl. 1). P. 455 (SATO240).

Bhandari S.K., Pashayan S., Liu I.L., Rasgon S.A., Kujubu D.A., Tom T.Y., Sim J.J. (2011) 25-Hydroxyvitamin D levels and hypertension rates. J Clin Hypertens (Greenwich) 13: 170–177.

Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C. et.al. Once-Yearly Zoledronic acid for treatment of postmenopausal osteoporosis // New England J. Medicine. 2007. Vol. 356. Р. 1809–1822.

Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., Satterfield S., Wallace R.B., Bauer D.C., Palermo L., Wehren L.E., Lombardi A., Santora A.C., Cummings S.R., FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006 Dec 27. 296(24): 2927–38.

Bolland M.J., Avenell A., Baron J.A., Grey A., MacLennan G.S., Gamble G.D., Reid I.R. (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: metaanalysis. BMJ. 341: c3691.

Bolland M.J., Barber P.A., Doughty R.N., Mason B., Horne A., Ames R., Gamble G.D., Grey A., Reid I.R. (2008) Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ. 336: 262–266.

Burgaz A., Orsini N., Larsson S.C., Wolk A. (2011) Blood 25-hydroxyvitamin D concentration and hypertension: a metaanalysis. J Hypertens 29: 636–645.

Burr D.B., Diab T., Koivunemi A., Koivunemi M., Allen M.R. Effects of 1 to 3 years’ treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res. 2009. Oct. 27(10): 1288–92.

Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., Felsenberg D., Huss H., Gibride J., Schimmer R.C., Delmas P.D. Effects of oral ibandronate administered daily or intermittenly on fracture risk in postmenopausal osteoporosis //J. Bone and Mineral Research. 2004. Vol. 19.

Р. 1241–1249.

Cramer J., Amonkar M.M., Hebborn A. et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis // Curr. Med. Res. Opin. 2005. V. 21. P. 1453–1460.

Cross H.S., Kallay, E. Regulation of the colonic vitamin D system for prevention of tumor progression: an update. Future Oncol. 2009, 5, 493–507.

Cryer B., Miller P., Petruschke R.A., Chen E., Geba G.P., Papp A.E. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2005. Mar 1. 21(5): 599–607.

Dobnig H., Pilz S., Scharnagl H., Renner W., Seelhorst U., Wellnitz B., Kinkeldei J., Boehm B.O., Weihrauch G., Maerz W. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 2008, 168, 1340–1349.

Emkey R., Koltun W., Beusterien K. et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO) // Curr Med Res Opin. 2005. 21(12): 1895–1903.

Felsenberg D., Hoffmeister B., Amling M., Seibel M.J., Fratzl P. Kiefemekrosen nach hoch dosierter bisphosphonattherapie // Dtsch Arzebl. 2006. Vol. 103. Р. 3078–3081.

Foley R.N., Collins A.J., Ishani A., Kalra P.A. (2008) Calciumphosphate levels and cardiovascular disease in communitydwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 156: 556–563;!!!Vestergaard P., Mollerup C.L., Frokjaer V.G., Christiansen P., Blichert-Toft M., Mosekilde L. (2003) Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 27: 216–222.